1 Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, mentioned different microhomology rates for well-supported integrations and weakly supported fragments, we investigated the microhomology distribution across 1,442 HPV16-positive breakpoints (all these breakpoints were manually checked and confirmed to be successfully assembled breakpoints). In accordance with the microhomology definition provided by Dyer et al.-where hybrid reads contained at the transition point a stretch of at least 2 bp aligning to both the human and viral genomes-the frequency of microhomologous sites of more than 2 bp in length was calculated for wellsupported and weakly supported sites ( Supplementary Fig. 7 ). Unlike the results described by Dyer et al., we observed only slightly higher microhomology rates at the weakly supported sites (~5% deviation) in comparison to the well-supported sites. Because microhomologous sites do not have to be located at the transition point 8 (that is, they may be several base pairs away from the breakpoint), we suspect that our method of calculating microhomology rate may have been different from that used by Dyer et al. However, even if there were differences between the microhomology rates of well-supported and weakly supported integrations, it does not necessarily follow that weakly supported integrations were generated from random ligation events. The reasons for the difference could be many. We speculate that one likely cause is that the well-supported integrations (DNA fragments of high copy number) may not use the exact same DNA repair pathway as the weakly supported integrations (DNA fragments of low copy number). Another cause may be that the major clones of cancer cells (containing the well-supported integrations) initiate different DNA repair mechanisms than those used by the minor clones of cancer cells (containing the weakly supported integrations). Many more experiments need to be performed to test these hypotheses. Third, regarding the small insertions between the HPV and host sequences, we think that they could also be considered as products of a microhomology-mediated DNA repair pathway 9, 10 . This point of view is quite consistent with our HPV integration data as well as with the analysis by Dyer et al. on mitochondrial insertion. Finally, when calculating microhomology, the length of microhomologous sites and the radius around the breakpoints need to be defined because these parameters are very important for the corresponding conclusions; please Exploring genomic alteration in pediatric cancer using ProteinPaint
To the Editor:
Genomic information about predisposing germline mutations in normal cells as well as acquired somatic lesions in cancer cells will enable the development and delivery of individualized cancer therapies. Ongoing global initiatives have shown that the spectra of somatic and germline genetic lesions in pediatric cancer are distinct from those found in adult cancer [1] [2] [3] . However, existing cancer genome data portals (cBioPortal 4 and the Catalogue of Somatic Mutations in Cancer (COSMIC) 5 ) have focused primarily on presenting data generated by adult cancer studies. They also lack features for exploring pathogenic germline mutations, gene fusions and mutation stratification by cancer subtype, all of which are of great importance in pediatric cancer.
Here we describe ProteinPaint, a web application for simultaneously visualizing genetic lesions (including sequence mutations and gene fusions) and RNA expression in pediatric cancers. The pediatric data set consists of 27,188 validated somatic coding lesions acquired at diagnosis or relapse from 17 subtypes of pediatric cancer, 252 pathogenic or loss-of-function germline lesions detected in >1,000 pediatric patients with cancer of 21 subtypes 6 and RNA sequencing (RNA-seq) data for 928 pediatric tumors from 36 subtypes (Supplementary Note). The data were compiled from five major studies (Supplementary Note) and will be expanded with the publication of additional pediatric cancer studies.
In ProteinPaint, genetic lesions from pediatric cancers are shown on a protein panel ( Fig. 1) with the option for a parallel view of a curated version of published somatic mutations in the COSMIC database (Supplementary Note). This parallel view enables the use of adult data for interpreting the significance of rare genetic lesions in pediatric cancer (Supplementary Figs.  1 and 2 ) and vice versa ( Supplementary  Fig. 3 ). To ensure consistency, all variants were reannotated with a modified version of ANNOVAR 7 . As an example, we show how this presentation has enabled the detection of aberrant splicing caused by recurrent 'silent' mutations in TP53. This finding also provided insight into the pathogenicity of matching germline variants found in patients with cancer predisposition syndromes ( Supplementary Fig. 1 and Supplementary Note). Additionally, presentation of mutant allele fractions in DNA and RNA facilitates evaluation of tumor heterogeneity, which is related to cancer relapse (Supplementary Fig. 3) , as well as detection of allelic imbalance in DNA or RNA caused by a second genetic or epigenetic event in tumors ( Supplementary Fig. 1 and Supplementary Note). Loss of heterozygosity (LOH), which was computed using the npg NATURE GENETICS | VOLUME 48 | NUMBER 1 | JANUARY 2016 generated by studies such as The Cancer Genome Atlas (TCGA) or individual research laboratories can be uploaded to ProteinPaint to enable data visualization and cross-study comparison for the broad genetic research community ( Supplementary Fig. 8 and Supplementary Tutorial). Manually curated protein domains have been incorporated for genes frequently mutated in pediatric cancer to facilitate the interpretation of mutation pathogenicity ( Fig. 1 and  Supplementary Fig. 6 ). ProteinPaint complements existing cancer genome portals by providing a comprehensive and intuitive view of pediatric cancer genomic data with advanced visualization features, as well as integration of expression and adult cancer data (Supplementary Figs. 6 and 7 , and Supplementary Note). Taken as a whole, these features make ProteinPaint a powerful tool for analyzing genomic data to enhance FLT3 in a leukemia with a kinase activation signature led to the discovery of high-level FLT3 amplification resulting from replication of an episome formed by a complex rearrangement involving three chromosomes ( Supplementary Fig. 5 and Supplementary Note).
ProteinPaint is designed to deliver a premium visualization experience with interactive and animated features. We implemented novel 'disc-on-stem' skewer graphs to depict the diverse prevalence, complex allelic alteration and temporal origin of mutations and gene fusions at a glance ( Fig. 1 and Supplementary Figs. 6  and 7) . Customized views include display of mutation and expression by cancer subtype or tumor tissue, dynamic zoom and integration of user-provided data, with new features implemented according to user feedback. Data in mutation annotation format (MAF) CONSERTING 8 algorithm in the pediatric cancer genomes we analyzed, is shown to further facilitate the identification of doublehit mutations affecting both alleles of a gene (Supplementary Fig. 4) .
The expression panel in ProteinPaint presents the rank and amount of gene expression for each sample, with superimposed box plots summarizing the expression range of the entire cohort or user-selected subtypes. Selecting a genetic lesion such as the PAX5-JAK2 fusion on the protein panel automatically highlights the mutated samples on the expression panel; in the case of PAX5-JAK2 fusion, the expression panel shows the aberrantly high expression of JAK2 caused by gene fusion (Fig. 1b) . Conversely, examination of aberrant expression in a tumor may lead to new insight into the causal genetic lesion. We show an example of how outlier expression of 
